4.7 Article

Analysis of SARS-CoV-2 known and novel subgenomic mRNAs in cell culture, animal model, and clinical samples using LeTRS, a bioinformatic tool to identify unique sequence identifiers

Journal

GIGASCIENCE
Volume 11, Issue -, Pages -

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/gigascience/giac045

Keywords

SARS-CoV-2; coronavirus; COVID-19; subgenomic mRNA; sgmRNA; transcriptional regulatory sequences; nanopore; direct RNA sequencing; RNA modification

Funding

  1. US Food and Drug Administration (FDA) Medical Countermeasures Initiative [75F40120C00085]
  2. MRC [MR/W005611/1]
  3. Centre of Excellence in Infectious Diseases Research (CEIDR)
  4. Coalition of Epidemic Preparedness Innovations (CEPI)
  5. Medical Research Council [MC_PC_19059, CV220-060]
  6. National Institute for Health Research (NIHR) [CO-CIN-01]
  7. Medical Research Council (MRC) [MC_PC_19059]
  8. NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool
  9. Public Health England (PHE)
  10. Liverpool School of Tropical Medicine
  11. University of Oxford [200907]
  12. NIHR HPRU in Respiratory Infections at Imperial College London with PHE [200927]
  13. Wellcome Trust
  14. Department for International Development (DID) [215091/Z/18/Z]
  15. Bill and Melinda Gates Foundation [OPP1209135]
  16. Liverpool Experimental Cancer Medicine Centre [C18616/A25153]
  17. NIHR Biomedical Research Centre at Imperial College London [IS-BRC-1215-20013]
  18. NIHR senior investigator award [201385]
  19. Alder Hey Charity
  20. National Institutes of Health Research (NIHR) [IS-BRC-1215-20013] Funding Source: National Institutes of Health Research (NIHR)
  21. Wellcome Trust [215091/Z/18/Z] Funding Source: Wellcome Trust
  22. Bill and Melinda Gates Foundation [OPP1209135] Funding Source: Bill and Melinda Gates Foundation

Ask authors/readers for more resources

The transcription strategy of SARS-CoV-2 for viral subgenomic mRNAs (sgmRNAs) plays a crucial role in nucleic acid diagnostics. LeTRS, a bioinformatics tool, has been developed to identify leader-TRS junctions and quantify sgmRNAs, providing insights into virus biology. LeTRS has been tested on different species and shown to have implications for transmission models and nucleic acid-based diagnostics.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a complex strategy for the transcription of viral subgenomic mRNAs (sgmRNAs), which are targets for nucleic acid diagnostics. Each of these sgmRNAs has a unique 5 ' sequence, the leader-transcriptional regulatory sequence gene junction (leader-TRS junction), that can be identified using sequencing. High-resolution sequencing has been used to investigate the biology of SARS-CoV-2 and the host response in cell culture and animal models and from clinical samples. LeTRS, a bioinformatics tool, was developed to identify leader-TRS junctions and can be used as a proxy to quantify sgmRNAs for understanding virus biology. LeTRS is readily adaptable for other coronaviruses such as Middle East respiratory syndrome coronavirus or a future newly discovered coronavirus. LeTRS was tested on published data sets and novel clinical samples from patients and longitudinal samples from animal models with coronavirus disease 2019. LeTRS identified known leader-TRS junctions and identified putative novel sgmRNAs that were common across different mammalian species. This may be indicative of an evolutionary mechanism where plasticity in transcription generates novel open reading frames, which can then subject to selection pressure. The data indicated multiphasic abundance of sgmRNAs in two different animal models. This recapitulates the relative sgmRNA abundance observed in cells at early points in infection but not at late points. This pattern is reflected in some human nasopharyngeal samples and therefore has implications for transmission models and nucleic acid-based diagnostics. LeTRS provides a quantitative measure of sgmRNA abundance from sequencing data. This can be used to assess the biology of SARS-CoV-2 (or other coronaviruses) in clinical and nonclinical samples, especially to evaluate different variants and medical countermeasures that may influence viral RNA synthesis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available